NETs Formation in Patients With Recurrent Pyogenic Infections (NETS)
Recruitment status was Recruiting
We aim to study if pathological NETs formation could be the underlying pathology among patients with recurrent infections and a normal screening of the immune system.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||The Ability of Neutrophils From Patients With Recurrent Infections to Produce Neutrophil Extracellular Traps (NET).|
- Measure NET formation in patients with recurrent infections [ Time Frame: One year ] [ Designated as safety issue: No ]
|Study Start Date:||May 2010|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Our laboratory at Meir Medical Center, Kfar Saba, is the country's main center for neutrophil function, and serves about 80% of Israel's population. Patients are referred subsequent to recurrent, persistent, or unusual infections and after completing preliminary screening of the immune system and ruling out a humoral, cellular or complement immune deficiency. Initial workup includes chemotaxis, superoxide production (SOP), and bactericidal activity (BA). Based on test findings, further evaluation for a qualitative phagocytic disorder is conducted. Overall, impairment of phagocytic activity is found in about 33% (impaired chemotaxis in 16%, SOP in 6%, and BA in 24%). In the other 67%, no impairment of the immune function is found that can explain their tendency for recurrent pyogenic infections.
In 2004 a novel function of the neutrophil was identified: formation of neutrophil extracellular traps (NETs). Apparently, neutrophils are able to extrude part of their cellular contents in the form of DNA, histones and proteases, to form extra cellular NETS that trap and kill bacterial pathogens without the need for phagocytosis. We aim to study if pathological NETs formation could be the underlying pathology among these patients with recurrent infections and a normal screening of the immune system.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01112592
|Contact: Ronit Gavrieli, MScemail@example.com|
|Meir Medical Center||Recruiting|
|Kfar Saba, Israel, 44281|
|Contact: Ronit Gavrieli, MSc 972-9-7472399 firstname.lastname@example.org|
|Principal Investigator: Baruch Wolach, MD|
|Sub-Investigator: Ronit Gavrieli, MSc|
|Sub-Investigator: Sivan Berger-Achituv, MD|
|Sub-Investigator: Tamar Kovalsky, Nurse|
|Principal Investigator:||Baruch Wolach, MD||Meir Medical Center|